Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced the launch of the Expansive.AI project today at the AIMed Conference in London, UK to an international audience of leaders in artificial intelligence (AI).
Systems Oncology, an AI-based biopharmaceutical company, and its partner, Systems Imagination, an AI platform technology company, will be leading a consortium to advance ExpansiveAI.
The project will be collaboratively developed through an open consortium of multi-disciplinary experts from both the technology and pharmaceutical industries, with the shared goal of advancing a new form of artificial intelligence capable of machine imagination.
In this context, ‘imagination’ means the computational ability to form original beliefs, to envision novel models, or to pose new hypotheses, all of which are beyond current AI systems.
The main problem ExpansiveAI addresses is the limited capacity of the human mind to imagine new scientific hypotheses or models of reality.
This limitation is particularly relevant to the field of drug discovery and development, where the number of original hypotheses human scientists can imagine is miniscule compared to what is discoverable.
The vision for ExpansiveAI is to go far beyond human imagination and create machines that can imagine and explore a more expansive universe of hypotheses and models, rapidly translating scientific data into breakthrough biomedical knowledge, in turn fueling a new renaissance in medicine.
The consortium will formalize alliances with additional leading pharmaceutical and technology companies in the coming months and announce the participating members at the inaugural ExpansiveAI meeting, which will be held at the AIMed conference in California on December 15, 2018.
About Systems Oncology: Systems Oncology (SO) combines multi-scalar systems modeling with machine learning and big-data to uncover breakthrough insights into cancer biology and expose new therapeutic vulnerabilities. These discoveries are then used to better develop truly novel therapeutic agents. SO has the experience and knowhow needed to intelligently translate scientific insights into smarter clinical development strategies and faster registration paths. It then partners with leading pharmaceutical companies to accelerate the development of breakthrough cancer treatments. Fundamental to the SO approach is a next-generation AI platform for translating scientific insights into innovative cancer therapies with unprecedented speed, scale, and precision.